drugset / Trial / NCT03121664

A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects

NCT03121664

Phase 1 Completed 11 enrolled Pfizer
CrossoverOpen-labelBasic science

Summary

The purpose of this study is to evaluate the impact of CYP3A4 inhibitor, itraconazole, on plasma concentration of PF-06649751 in healthy subjects

Timeline

Start
2017-04-07
Primary completion
2017-09-14
Completion
2017-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg
Subject Tavapadon Small molecule 1 mg

Indications

No indication recorded.